Figure 1
Figure 1. CD16 expression on Vδ2neg γδ T cells and HCMV. (A) Six-color staining with mAbs directed against CD3, Vδ2, TCRγδ, CD27, CD45RA, and CD16 was performed on PMBC from 32 kidney transplant recipients (KTRs) and 28 healthy volunteers divided in HCMV-seropositive (HCMV) or HCMV-seronegative (no HCMV) individuals. Left panels: staining on 1 representative patient. Right panels: results from the 28 healthy donors and 32 KTRs. Data are expressed as medians (range) for the whole population. (B) The 32 KTRs included in the study were divided according to HSV1/2 (top panel) or HBV serologies (bottom panel, infected = anti-Hbc positive, vaccinated = anti-Hbs positive) and the proportion of CD16pos Vδ2neg γδ T cells was evaluated in each group. (C) Monitoring of CD16pos Vδ2neg γδ T cells in 1 HCMV-seronegative KTR who received a kidney from a seropositive donor and who developed HCMV infection (represented as gray bar).

CD16 expression on Vδ2neg γδ T cells and HCMV. (A) Six-color staining with mAbs directed against CD3, Vδ2, TCRγδ, CD27, CD45RA, and CD16 was performed on PMBC from 32 kidney transplant recipients (KTRs) and 28 healthy volunteers divided in HCMV-seropositive (HCMV) or HCMV-seronegative (no HCMV) individuals. Left panels: staining on 1 representative patient. Right panels: results from the 28 healthy donors and 32 KTRs. Data are expressed as medians (range) for the whole population. (B) The 32 KTRs included in the study were divided according to HSV1/2 (top panel) or HBV serologies (bottom panel, infected = anti-Hbc positive, vaccinated = anti-Hbs positive) and the proportion of CD16pos Vδ2neg γδ T cells was evaluated in each group. (C) Monitoring of CD16pos Vδ2neg γδ T cells in 1 HCMV-seronegative KTR who received a kidney from a seropositive donor and who developed HCMV infection (represented as gray bar).

Close Modal

or Create an Account

Close Modal
Close Modal